Covestor’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Covestor's RAPP Position: Q3 2026 in Review
Covestor reduced its Rapport Therapeutics (RAPP) stake by 59% in Q3 2026, selling an estimated $432 and leaving 7 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2921.
Covestor first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $1K in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Covestor held 7 shares of Rapport Therapeutics worth $0 as of Q3 2026.
- Covestor sold 10 Rapport Therapeutics shares in Q3 2026, an estimated $432.
- Rapport Therapeutics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2921 holding.
- Covestor first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Covestor's Rapport Therapeutics position peaked at $1K in Q2 2026.
- 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.